BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 21122066)

  • 1. Primary cutaneous diffuse large B-cell lymphoma, leg-type, treated with a modified R-CHOP immunochemotherapy - diagnostic and therapeutic challenges.
    Wobser M; Kneitz H; Bröcker EB; Becker JC
    J Dtsch Dermatol Ges; 2011 Mar; 9(3):204-11. PubMed ID: 21122066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary cutaneous diffuse large B cell lymphoma, leg type.
    Dongre A; Kar S; Gondse S; Gangane N; Mehra BK
    Indian J Dermatol Venereol Leprol; 2011; 77(2):212-4. PubMed ID: 21393962
    [No Abstract]   [Full Text] [Related]  

  • 3. Primary cutaneous large B-cell lymphoma, leg type, successfully treated with rituximab plus chemotherapy.
    Posada García C; Florez A; Pardavila R; Garcia-Cruz A; Amador L; Alvarez M; Alberte LM; Cruces MJ
    Eur J Dermatol; 2009; 19(4):394-5. PubMed ID: 19467966
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma.
    Colovic N; Jurisic V; Terzic T; Atkinson HD; Colovic M
    Arch Dermatol Res; 2009 Oct; 301(9):689-92. PubMed ID: 19495780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
    J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An atypical presentation of primary cutaneous diffuse B-cell lymphoma, leg type].
    Brouillard C; Granel-Brocard F; Montagne K; Bastien C; Barbaud A; Schmutz JL
    Ann Dermatol Venereol; 2011; 138(8-9):601-4. PubMed ID: 21893235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous plasmablastic lymphoma.
    Jambusaria A; Shafer D; Wu H; Al-Saleem T; Perlis C
    J Am Acad Dermatol; 2008 Apr; 58(4):676-8. PubMed ID: 18342714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients.
    Guyot A; Ortonne N; Valeyrie-Allanore L; Bagot M
    Arch Dermatol; 2010 Jan; 146(1):89-91. PubMed ID: 20083704
    [No Abstract]   [Full Text] [Related]  

  • 10. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
    Lee KW; Kim DY; Yun T; Kim DW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
    Cancer; 2003 Dec; 98(12):2651-6. PubMed ID: 14669285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab.
    Grange F; Maubec E; Bagot M; Beylot-Barry M; Joly P; Dalle S; Delaporte E; Dereure O; Bachelez H; Vergier B; Petrella T; D'Incan M
    Arch Dermatol; 2009 Mar; 145(3):329-30. PubMed ID: 19289772
    [No Abstract]   [Full Text] [Related]  

  • 12. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP.
    Lin PC; Hsiao LT; Poh SB; Wang WS; Yen CC; Chao TC; Liu JH; Chiou TJ; Chen PM
    Ann Hematol; 2007 Feb; 86(2):95-100. PubMed ID: 17031689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Ninomiya S; Hara T; Tsurumi H; Hoshi M; Kanemura N; Goto N; Kasahara S; Shimizu M; Ito H; Saito K; Hirose Y; Yamada T; Takahashi T; Seishima M; Takami T; Moriwaki H
    Ann Hematol; 2011 Apr; 90(4):409-16. PubMed ID: 20938662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid diffuse large B cell lymphoma (DLBCL) following thyroid medullary cancer: long-term complete remission with R-CHOP therapy.
    Dai CW; Zhang GS; Pei MF; Shen JK
    Ann Hematol; 2009 Jul; 88(7):701-2. PubMed ID: 19015853
    [No Abstract]   [Full Text] [Related]  

  • 16. Complete remission of primary cutaneous intravascular large B-cell lymphoma with R-CHOP followed by rituximab monotherapy.
    Pantelaki I; Tigges C; Nußbaum T; Oellig F; Wieland U; Kreuter A
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28508527
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
    Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
    N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic factors analysis for R-CHOP regimen therapy in diffuse large B cell lymphoma].
    Shen Y; Yao Y; Li JM; Chen QS; You JH; Zhao HJ; Chen S; Shen ZX
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):252-7. PubMed ID: 18843980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case report of composite lymphoma].
    Wu J; Wang ZC; Chen XD
    Ai Zheng; 2007 Apr; 26(4):447. PubMed ID: 17430672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.